Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Yttrium-90 ibritumomab tiuxetan with rituximab for previously untreated marginal zone lymphoma; the study is completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: University of Miami | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-01